CIPLA VALGANCICLOVIR valganciclovir (as hydrochloride) 450 mg tablet bottle

País: Austràlia

Idioma: anglès

Font: Department of Health (Therapeutic Goods Administration)

ingredients actius:

valganciclovir hydrochloride, Quantity: 496.3 mg (Equivalent: valganciclovir, Qty 450 mg)

Disponible des:

Cipla Australia Pty Ltd

Designació comuna internacional (DCI):

Valganciclovir hydrochloride

formulario farmacéutico:

Tablet, film coated

Composición:

Excipient Ingredients: povidone; stearic acid; crospovidone; microcrystalline cellulose; titanium dioxide; hypromellose; macrogol 6000; iron oxide red

Vía de administración:

Oral

Unidades en paquete:

60 tablets

tipo de receta:

(S4) Prescription Only Medicine

indicaciones terapéuticas:

CIPLA VALGANCICLOVIR is indicated for the treatment of cytomegalovirus (CMV) retinitis in adult patients with acquired immunodeficiency syndrome (AIDS).,CIPLA VALGANCICLOVIR is indicated for the prophylaxis of CMV disease in adult and paediatric solid organ transplantation (SOT) patients who are at risk.

Resumen del producto:

Visual Identification: Pink coloured, capsule shaped, biconvex film coated tablet plain on both sides; Container Type: Bottle; Container Material: HDPE; Container Life Time: 24 Months; Container Temperature: Store below 25 degrees Celsius; Container Closure: Child resistant closure

Estat d'Autorització:

Licence status A

Data d'autorització:

2016-09-02